|
||||||
In Business 29 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[TAK-165]
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
10 mg |
134 |
93 |
81 |
12600 |
| ||
|
25 mg |
249 |
174 |
151 |
23500 |
| ||
|
50 mg |
376 |
262 |
228 |
35500 |
| ||
|
100 mg |
572 |
399 |
347 |
54000 |
| ||
|
200 mg |
899 |
627 |
545 |
84800 |
| ||
|
500 mg |
1760 |
1227 |
1066 |
166100 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Prices and Purity LC Labs vs. Other Suppliers |
|---|
M.W. 468.47
C25H23F3N4O2
[366017-09-6]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Mubritinib is a potent inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase.
For inhibitory testing, HER2 was expressed in the following cell types: bladder (HT1376, UMUC3, T24), kidney (ACHN), and prostate (DU145, LNCaP, LN-REC4). IC50 values for mubritinib for the bladder cancer cell lines varied from 0.09 µM to greater than 25 µM. All of the prostate cancer cell lines studied were sensitive (IC50 = 0.053-4.6 µM) to mubritinib, but ACHN cells were relatively less sensitive. In the xenograft model, treatment with mubritinib for 14 days significantly inhibited growth of UMUC-3 (22.9%), ACHN (26.0%), and LN-REC4 (26.5%) when compared to control. Nagasawa, J., et al. "Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo." Int. J. Urol. 13: 587-592 (2006).
Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
Not available in some countries; not available to some institutions; not available for some uses.
© 1990-2010 LC Laboratories All rights reserved.